Drugs Information:
Emapalumab
Basic Information
|
||
| ID | DDInter634 | |
| Drug Type | biotech | |
| Protein Chemical Formula | C6430H9898N1718O2038S46 | |
| Protein Average Weight | 154400.000 | |
| CAS Number | 1709815-23-5 | |
| Description | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.[L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845] | |
| ATC Classification | L04AA39 | |
| Sequences | None | |
| Useful Links | DrugBank Wikipedia | |
Interactions with
Emapalumab
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|